Resources
5 Results (showing 1 - 5)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 11/11/2022 (updated 3/27/2024)
OMNI Institute, in partnership with the JBS RCORP-TA team, created the 2022-2023 RCORP-TA Data Learning Collaborative (LC) for grantees to come together and share knowledge, talk through challenges, and build relationships with one another. This LC will build upon the foundation established in the prior 2022 RCORP-TA Data Learning Collaborative.
Posted 4/25/2023 (updated 3/27/2024)
This page contains resources to support grantees in collecting, managing and sharing their RCORP data. If you are in need of PIMS data collection guidance, please visit the RCORP Grantee Data Collection Resources (Implementation, MAT Expansion, and NAS) page to access the PIMS Data Collection Resource, checklist, and workbook.
Posted 4/26/2023 (updated 3/27/2024)
OMNI Institute, in partnership with the JBS RCORP-TA team, created the Spring 2023 Data Learning Collaborative for all RCORP grant recipients. These sessions built the foundation for data learning, and we dove into data-related topics during each month’s skills-building session.
Posted 5/19/2020 (updated 3/28/2024)
In 2016, the United States Congress authorized and appropriated funding to fight the opioid epidemic through the Department of Health and Human Services . Among other initiatives, the Comprehensive Addiction and Recovery Act (CARA) gave the Substance Abuse and Mental Health Services Administration authority and support to implement new grant programs focused on preventing overdose and treating individuals with OUD.
Posted 8/11/2020 (updated 4/2/2024)
Non-fatal opioid overdose (NFOO) is a significant cause of opioid-related morbidity in the United States. As the number of NFOOs continues to grow, it is important to understand the short- and long-term consequences of NFOO. This report examines the existing literature on the acute and chronic health and functional outcomes of individuals who experience NFOO, and also identifies differences in outcomes for NFOOs involving illicitly-manufactured fentanyl.